Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) is one of the most undervalued pharma stocks
TheFly reported on May 11 that Piper Sandler reduced its price target on AMPH from $25 to $21 while maintaining a Neutral stance on the stock following the company’s quarterly results. The firm noted that AMPH has several complex generic products and branded opportunities in its pipeline, but there is limited clarity on when these programs will begin to generate meaningful results. This lack of visibility into the timing of potential pipeline catalysts contributed to the revised outlook.
Earlier on May 7, Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its financial results for the first quarter ended March 31, 2026. The company posted net revenues of $171.2 million for the period. Reported GAAP net income came in at $6.4 million, translating to earnings of $0.14 per share.